Lutetium-177 Market and Pipeline Analysis–Forecast to 2026
|Publishing Date :||February, 2020|
|Report Code :||HCPH0003|
Single license $3,600
Site license $5,400
Global license $7,200
Note: The report would be dispatched after confirmation of payment
- “Lutetium-177 Market and Pipeline Analysis–Forecast to 2026” gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of GEP-NET, prostate cancer and other diseases. The report covers marketed products details and also drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on Lu-177 labeled monoclonal antibodies and peptides for various indications that are in clinical trials, FDA and CE approved products (Lutathera).
- The report covers the patient population, treatment cost, total addressable market and penetration for GEP-NET and Prostate cancer. It covers list of nuclear reactors that have potential to produce Lu-177 both medium and high flux reactor with their locations all over the world. It also focuses on supply chain analysis and market dynamics (DROT) of Lu-177.
- This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Lu-177 global market. The report also provide strategic insights on some of the molecules which will eventually be launched in the next few years.
- Market Analysis
- In market analysis section, global GEP-NET and Prostate cancer market are indicated along with the Lu-177 therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Lu-177 isotope is forecasted from 2019 to 2026.
- Lu-177 players and their production capacities
- Lu-177 market dynamics.
- Lu-177 related deals analysis.
- Funding scenario in Lu-177 market
- Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET & Prostate cancer).
- Pipeline Analysis
- Pipeline Analysis by molecule type
- Monoclonal Antibodies labelled pipeline analysis
- Peptide labelled pipeline analysis
- Pipeline analysis by leading players & their molecule analysis
- Key Players Analysis
- The key player’s analysis section provides an in-depth understanding of various companies working on Lu-177 and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
- Global key players overview
- Global key players Pipeline data (discovery, pre-clinical & clinical development)
- Global key players deals (collaborations, partnership, licensing agreements, grants, funds)
- 1 REPORT DESCRIPTION
- 2 INTRODUCTION
- 3 EXECUTIVE SUMMARY
- 4 MARKET DYNAMICS (DROT)
- 5 SUPPLY CHAIN ANALYSIS
- 5.1 Direct
- 5.2 Indirect
- 6 DEALS
- 6.1 Acquisition
- 6.2 License Agreement
- 6.3 Partnership
- 6.4 Collaboration
- 7 FUNDING SCENARIO
- 8 MARKET DATA
- 8.1 TAM and Penetration - GEP-NET (Region)
- 8.2 TAM -Prostate Cancer (Region)
- 9 ASSUMPTIONS
- 10 PIPELINE ANALYSIS
- 10.1 Development Stage
- 10.2 Indications
- 10.3 Major Players
- 10.4 Molecule Type
- 11 RIT BASED PIPELINE ANALYSIS
- 11.1 By Phase
- 11.2 By Indications
- 11.3 Clinical trial update on Phase 3 and Phase 2b molecules
- 12 PRRT BASED PIPELINE ANALYSIS
- 12.1 By Phase
- 12.2 By Indications
- 12.3 Clinical trial update on Phase 3 molecules
- 13 MAJOR PLAYERS
- 13.1 Company Profiles
- 13.2 Overview
- 13.3 Pipeline
- 14 MEDIUM FLUX REACTORS AND THEIR LOCATION
- 15 HIGH FLUX REACTORS AND THEIR LOCATION
- 16 SUPPLIERS AND ANNUAL ESTIMATED PRODUCTION OF Lu-177
- 17 REFERENCES